Skip to main content

Table 3 Summary of the solicited treatment emergent adverse events (TEAEs) reported at least once by 37 patients

From: Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

  TEAEs (% of patients) Possibly or probably drug-related TEAEs (% of patients)
Description FD ASAQ NF ASAQ All FD ASAQ NF ASAQ All
(N = 26) (N = 28) (N = 54) (N = 26) (N = 28) (N = 54)
At least one TEAE 18 (69.2) 19 (67.9) 37 (68.5) 5 (19.2) 5 (17.9) 10 (18.5)
Headache 10 (38.5) 12 (42.9) 22 (40.7) - - -
Weakness 8 (30.8) 11 (39.3) 19 (35.2) - 2 (7.1) 2 (3.7)
Anorexia 7 (26.9) 7 (25.0) 14 (25.9) 1 (3.8) - 1 (1.9)
Nausea 6 (23.1) 8 (28.6) 14 (25.9) - - -
Abdominal pain 6 (23.1) 7 (25.0) 13 (24.1) 1 (3.8) 1 (3.6) 2 (3.7)
Itching 6 (23.1) 3 (10.7) 9 (16.7) 3 (11.5) 2 (7.1) 5 (9.3)
Vomiting 4 (15.4) 2 (7.1) 6 (11.1) - - -
Diarrhoea 2 (7.7) 2 (7.1) 4 (7.4) - 1 (3.6) 1 (1.9)
Rhinitis 2 (7.7) 2 (7.1) 4 (7.4) 1 (3.8) - 1 (1.9)
Cough 1 (3.8) 2 (7.1) 3 (5.6) - - -
  1. All FD vs NF ASAQ comparisons were not statistically significant.
\